Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women

被引:162
作者
Fairley, C. K. [1 ]
Hocking, J. S.
Gurrin, L. C. [2 ]
Chen, M. Y. [1 ]
Donovan, B. [3 ]
Bradshaw, C. S. [4 ,5 ]
机构
[1] Univ Melbourne, Alfred Hosp, Melbourne Sexual Hlth Ctr, Carlton, Vic 3053, Australia
[2] Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Carlton, Vic 3053, Australia
[3] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2052, Australia
[4] Monash Univ, Alfred Hosp, Melbourne Sexual Hlth Ctr, Prahran, Vic, Australia
[5] Monash Univ, Dept Epidemiol & Prevent Med, Prahran, Vic, Australia
基金
英国医学研究理事会;
关键词
PARTICLE VACCINE; SUSTAINED EFFICACY; CONTROLLED-TRIAL; FOLLOW-UP; TYPE-16;
D O I
10.1136/sti.2009.037788
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: This study aimed to determine if the Australian human papillomavirus (HPV) vaccination programme has had a population impact on presentations of genital warts. Methods: Retrospective study comparing the proportion of new clients with genital warts attending Melbourne Sexual Health Centre (MSHC) from January 2004 to December 2008. Australia provided free quadrivalent HPV vaccine to 12-18-year-old girls in a school-based programme from April 2007, and to women 26 years and younger through general practices from July 2007. Results: 36 055 new clients attended MSHC between 2004 and 2008 and genital warts were diagnosed in 3826 (10.6%; 95% CI 10.3 to 10.9). The proportion of women under 28 years with warts diagnosed decreased by 25.1% (95% CI 30.5% to 19.3%) per quarter in 2008. Comparing this to a negligible increase of 1.8% (95% CI 0.2% to 3.4%) per quarter from the start of 2004 to the end of 2007 also in women under 28 years generates strong evidence of a difference in these two trends (p < 0.001). There was no evidence of a difference in trend for the quarterly proportions before and after the end of 2007 for any other subgroup, and on only one occasion was there strong evidence of a trend different to zero, for heterosexual men in 2008 in whom the average quarterly change was a decrease of 5% (95% CI 0.5% to 9.4%; p = 0.031). Conclusions: The data suggest that a rapid and marked reduction in the incidence of genital warts among vaccinated women may be achievable through an HPV vaccination programme targeting women, and supports some benefit being conferred to heterosexual men.
引用
收藏
页码:499 / 502
页数:4
相关论文
共 13 条
  • [1] Quadrivalent human papillomavirus vaccine
    Barr, Eliav
    Tamms, Gretchen
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) : 609 - 617
  • [2] GIULIANO A, 2008, EUROGIN 2008 C JOIN
  • [3] Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
    Harper, DM
    Franco, EL
    Wheeler, CM
    Moscicki, AB
    Romonowski, B
    Roteli-Martins, CM
    Jenkins, D
    Schuind, A
    Clemens, SAC
    Dubin, G
    [J]. LANCET, 2006, 367 (9518) : 1247 - 1255
  • [4] The economic burden of noncervical human papillomavirus disease in the United States
    Hu, Delphine
    Goldie, Sue
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 198 (05) : 500.e1 - 500.e7
  • [5] Economic evaluation of human papillomavirus vaccination in the United Kingdom
    Jit, Mark
    Choi, Yoon Hong
    Edmunds, W. John
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7665): : 331 - 335
  • [6] A controlled trial of a human papillomavirus type 16 vaccine
    Koutsky, LA
    Ault, KA
    Wheeler, CM
    Brown, DR
    Barr, E
    Alvarez, FB
    Chiacchierini, LM
    Jansen, KU
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) : 1645 - 1651
  • [7] A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
    Kulasingam, Shalini
    Connelly, Luke
    Conway, Elizabeth
    Flocking, Jane S.
    Myers, Evan
    Regan, David G.
    Roder, David
    Ross, Jayne
    Wain, Gerard
    [J]. SEXUAL HEALTH, 2007, 4 (03) : 165 - 175
  • [8] Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia - A Randomized controlled trial
    Mao, C
    Koutsky, LA
    Ault, KA
    Wheeler, CM
    Brown, DR
    Wiley, DJ
    Alvarez, FB
    Bautista, OM
    Jansen, KU
    Barr, E
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) : 18 - 27
  • [9] Effects of a change from an appointment service to a walk-in triage service at a sexual health centre
    Tideman, RL
    Pitts, MK
    Fairley, CK
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2003, 14 (12) : 793 - 795
  • [10] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
    Villa, L. L.
    Costa, R. L. R.
    Petta, C. A.
    Andrade, R. P.
    Paavonen, J.
    Iversen, O-E
    Olsson, S-E
    Hoye, J.
    Steinwall, M.
    Riis-Johannessen, G.
    Andersson-Ellstrom, A.
    Elfgren, K.
    von Krogh, G.
    Lehtinen, M.
    Malm, C.
    Tamms, G. M.
    Giacoletti, K.
    Lupinacci, L.
    Railkar, R.
    Taddeo, F. J.
    Bryan, J.
    Esser, M. T.
    Sings, H. L.
    Saah, A. J.
    Barr, E.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (11) : 1459 - 1466